The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom

MLA

Michele A. Kohli, et al. “The Cost-Effectiveness of an Adjuvanted Quadrivalent Influenza Vaccine in the United Kingdom.” Human Vaccines & Immunotherapeutics, vol. 17, no. 11, Nov. 2021, pp. 4603–10. EBSCOhost, https://doi.org/10.1080/21645515.2021.1971017.

APA

Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Michael Drummond, & Milton C. Weinstein. (2021). The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom. Human Vaccines & Immunotherapeutics, 17(11), 4603–4610. https://doi.org/10.1080/21645515.2021.1971017

Chicago

Michele A. Kohli, Michael Maschio, Joaquin F. Mould-Quevedo, Michael Drummond, and Milton C. Weinstein. 2021. “The Cost-Effectiveness of an Adjuvanted Quadrivalent Influenza Vaccine in the United Kingdom.” Human Vaccines & Immunotherapeutics 17 (11): 4603–10. doi:10.1080/21645515.2021.1971017.